认证基因工程临床相关的多发性骨髓瘤小鼠模型-猫眼课题宝

认证基因工程临床相关的多发性骨髓瘤小鼠模型

批准号：

10310482

负责人：

Marta Chesi

金额：

$37.21万

依托单位：

MAYO CLINIC ARIZONA

依托单位国家：

美国

项目类别：

财政年份：

2018

资助国家：

美国

项目状态：

已结题

起止时间：

2018-12-07 至 2023-11-30

来源：

https://reporter.nih.gov/project-details/10310482

关键词：

Address Amino Acid Sequence Anemia B-Lymphocytes Bacterial Artificial Chromosomes Binding Biological Biological Models Biology Bone Diseases Bone Marrow Cell Line Cell Survival Cell Transplantation Cells Clinical Combination Drug Therapy Combined Modality Therapy Complex Credentialing Dependence Drug Receptors Drug resistance Drug usage Engineering Generations Genes Genetic Genetic Engineering Genomic approach Glucocorticoids Goals Hematologic Neoplasms Home Human Human Characteristics Immune system Immunocompetent Immunoglobulin Class Switching Immunoglobulin Somatic Hypermutation Immunoglobulins Immunomodulators Immunotherapy Impairment Indolent Interferon Type II Kidney Mediating Modeling Monoclonal gammopathy of uncertain significance Multiple Myeloma Mus Mutation Newly Diagnosed Patients Pharmaceutical Preparations Population Pre-Clinical Model Precancerous Conditions Predictive Value Proteasome Inhibitor Publishing Refractory Regulatory Element Relapse Research Personnel Resistance Role Splenocyte Structure of germinal center of lymph node T-Cell Proliferation Thalidomide Transcription Factor 3 Transgenic Mice Transplantation Ubiquitin Validation Variant Vertebral column Work clinical practice clinical predictors clinically relevant drug-sensitive experimental study gene product genetic manipulation human disease in vivo in vivo Model lenalidomide mouse model neoplasm immunotherapy neoplastic cell novel plasma cell differentiation pleiotropism pomalidomide post-transplant receptor recruit relapse patients response tumor tumor immunology tumor progression

项目摘要

项目成果

Marta Chesi的其他基金

相似基金

相关文献

中文摘要

翻译

项目摘要/摘要沙利度胺(THAL)及其衍生物来那度胺(LEN)和泊马度胺(POM)是免疫的用于治疗多发性骨髓瘤(MM)的调节药物(IMids)等恶性血液病。尽管它们代表着治疗这两种新疾病的骨干确诊和复发/难治性多发性骨髓瘤患者，他们的临床应用大多仍是经验性的，因为缺乏合适的体内模型系统来研究其复杂的作用机制。小鼠细胞是由于IMiD结合区的氨基酸序列不同而对IMiDS产生固有抗性克雷布隆(CRBN)。通过构建我们广泛验证的VK*MYC转基因小鼠模型嗯，我们培育了一种新型的转基因小鼠VK*MYChCRBN，表达了完整的人CRBN (HCRBN)基因受其内源性调控元件的控制，使其对IMIDD敏感。正如之前针对VK*MYC模型所做的那样，我们将广泛描述新的VK*MYChCRBN 模型，并将使用它来了解IMiD对肿瘤和免疫系统的影响最终目标是为临床实践提供信息。

英文摘要

Project Summary/Abstract Thalidomide (Thal) and its derivatives, Lenalidomide (Len) and Pomalidomide (POM), are immune modulatory drugs (IMiDs) used in the treatment of multiple myeloma (MM) and few other hematological malignancies. Although they represent the backbone treatment for both newly diagnosed and relapse/refractory MM patients, their clinical use remains mostly empirical because of lack of suitable in vivo model systems to study their complex mechanisms of action. Murine cells are intrinsically resistant to IMiDs because of different amino acid sequence in the IMiD binding domain of cereblon (CRBN). By building upon our extensively validated Vk*MYC transgenic mouse model of MM, we have generated a novel transgenic mouse, Vk*MYChCRBN, expressing the full human CRBN (hCRBN) gene under the control of its endogenous regulatory elements, rendering it IMiD sensitive. As previously done for the Vk*MYC model, we will extensively characterize the new Vk*MYChCRBN model and will use it to understand the IMiD effects on the tumor and the immune system with the ultimate goal to inform clinical practice.

期刊论文(0)

专著(0)

科研奖励(0)

会议论文